This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Chemours (CC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Chemours (CC) closed the most recent trading day at $27.28, moving +1.83% from the previous trading session.
Should Value Investors Buy Chemours (CC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Buy Stocks for January 25th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Is The Chemours (CC) Outperforming Other Basic Materials Stocks This Year?
by Zacks Equity Research
Is (CC) Outperforming Other Basic Materials Stocks This Year?
The Zacks Analyst Blog Highlights: Altus Midstream, Chemours, D.R. Horton, DocuSign and Harley-Davidson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Altus Midstream, Chemours, D.R. Horton, DocuSign and Harley-Davidson
New Strong Buy Stocks for January 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Wall Street Unfazed by Lingering Unease in Washington: 5 Picks
by Tirthankar Chakraborty
Expectations about stimulus package, Fed's supportive stance, and vaccine rollout have helped investors remain optimistic, which calls for investing in growth stocks like D.R. Horton (DHI) and DocuSign (DOCU).
3 Reasons Why Chemours (CC) Is a Great Growth Stock
by Zacks Equity Research
Chemours (CC) possesses solid growth attributes, which could help it handily outperform the market.
Are You Looking for a Top Momentum Pick? Why Chemours (CC) is a Great Choice
by Zacks Equity Research
Does Chemours (CC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Chemours (CC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
6 Stocks Trading Near 52-Week Highs That Can Appreciate Further
by Anirudha Bhagat
Investors target stocks that have been on a bullish run, lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.
Chemours (CC) Stock Rallies 79% in 6 Months: What's Driving It?
by Zacks Equity Research
Chemours (CC) gains on a recovery in demand from the coronavirus-induced slowdown, strong execution and its cost-reduction measures.
Global Chemical Output Leaps for Sixth Straight Month: 5 Picks
by Anindya Barman
The chemical industry has recovered from the pandemic-led slump and looks set for an upturn this year on a rebound in end-market demand. CBT, HUN, CC, PPG and CE to gain from the industry's recovery.
5 Chemical Stocks Poised to Maintain Winning Streak in 2021
by Anindya Barman
A rebound in China, demand upturn across major markets and recovering manufacturing activities augur well for the chemical industry heading into 2021.
What Makes Chemours (CC) Stock a Solid Choice Right Now
by Zacks Equity Research
Chemours (CC) benefits from demand recovery, cost-management initiatives and strong execution.
4 Diversified Chemical Stocks Set to Ride the Industry's Upturn
by Anindya Barman
An uptick in demand in key end-markets from pandemic-led shocks should enable the Zacks Chemicals Diversified industry to thrive. PPG, CC, CBT and KOP are set to gain from improving industry fundamentals and strategic actions.
Is Chemours Company (CC) a Good Value Investor Stock Now?
by Zacks Equity Research
Let's see if The Chemours Company (CC) stock is a good choice for value-oriented investors right now from multiple angles.
New Strong Buy Stocks for December 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
US Chemical Industry Set for Strong Rebound in 2021: 5 Picks
by Anindya Barman
The U.S. chemical industry is poised for an upturn next year on a rebound across major end-markets and a recovery in chemical exports.
Chemours (CC) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Chemours (CC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Chemours (CC) Up 30% in 3 Months: What's Driving the Rally?
by Zacks Equity Research
Chemours (CC) gains on a recovery in demand from the coronavirus-induced slowdown and its cost-reduction measures.
Is Chemours (CC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours (CC) Up 19.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Chemical Output Leaps as Recovery Continues to Take Hold
by Anindya Barman
A rebound in demand across major end markets has put the wind back in the sails of the chemical industry.
Here's Why You Should Add Chemours (CC) to Your Portfolio
by Zacks Equity Research
Chemours (CC) benefits from demand recovery across its markets and its cost-cutting actions.